Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on October 28, 2008
JNCI Journal of the National Cancer Institute 2008 100(21):1557; doi:10.1093/jnci/djn341
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/21/1557    most recent
djn341v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Di Maio, M.
Right arrow Articles by Perrone, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Maio, M.
Right arrow Articles by Perrone, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

CORRESPONDENCE

Re: Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

Massimo Di Maio, Bruno Daniele, Ciro Gallo, Francesco Perrone

Affiliations of authors: Clinical Trials Unit, National Cancer Institute, Naples, Italy (MDM, FP); Oncology Unit, G. Rummo Hospital, Benevento, Italy (BD); Department of Medicine and Public Health, Second University of Naples, Naples, Italy (CG)

Correspondence to: Francesco Perrone, MD, PhD, Clinical Trials Unit, National Cancer Institute, Naples, Italy (e-mail: fr.perrone@agora.it).

The first 10% of the full text of this article appears below.

The commentary on design and endpoints of clinical trials in hepatocellular carcinoma (HCC) by Llovet et al. (1) gives a relevant contribution to the methodological improvement of clinical research in this setting. We appreciate the panel's recognition that the proposed treatment algorithm for HCC patients remains based on very low strength of evidence, with . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?